Loading, Please Wait...

CST: 20/11/2019 08:05:58   

miRagen Therapeutics to Report Third Quarter 2019 Financial Results and Host a Conference Call

29 Days ago

BOULDER, Colo., Oct. 22, 2019 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company developing proprietary RNA-targeted therapies with a specific focus on microRNAs, will host a conference call and webcast on Thursday, November 7th, at 4:30 p.m. ET to discuss a corporate update and results for the third quarter of 2019.

To access the call, please dial 855-327-6837 in the U.S. or 631-891-4304 outside the U.S. and provide the conference ID number: 10007827. A live webcast can be accessed from the Investors and Media section of the miRagen Therapeutics website. A replay of this conference call will be available on miRagen’s website approximately one hour after the event.

About miRagen Therapeutics, Inc.
miRagen Therapeutics, Inc. is a clinical-stage biopharmaceutical company discovering and developing proprietary RNA-targeted therapies with a specific focus on microRNAs and their role in diseases where there is a high unmet medical need. miRagen has three clinical stage product candidates, cobomarsen, remlarsen, and MRG-110. miRagen’s clinical product candidate for the treatment of certain cancers, cobomarsen, is an inhibitor of microRNA-155, which is found at abnormally high levels in malignant cells of several blood cancers. miRagen’s clinical product candidate for the treatment of pathological fibrosis, remlarsen, is a replacement for microRNA-29, which is found at abnormally low levels in a number of pathological fibrotic conditions, including cutaneous, cardiac, renal, hepatic, pulmonary and ocular fibrosis, as well as in systemic sclerosis. MRG-110, an inhibitor of microRNA-92, is miRagen’s product candidate for the treatment of heart failure and other ischemic disease. In addition to these programs, miRagen is developing a pipeline of preclinical product candidates. The goal of miRagen’s translational medicine strategy is to progress rapidly to first-in-human studies once it has established the pharmacokinetics, pharmacodynamic, safety, and manufacturability of the product candidate in preclinical studies. For more information and scientific presentations, please visit www.miragen.com. For information on clinical trials please visit www.clinicaltrials.gov.

Investor Relations Contact:                                                 
Dan Ferry
LifeSci Advisors
(617) 430-7576
daniel@lifesciadvisors.com 

 

Is your business listed correctly on America’s largest city directory network of 1,000 portals?